Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA

D. Yu, A.H. Tan, X. Hu, V. Athanasopoulos, N. Simpson, D.G. Silva, A. Hutloff, K.M. Giles, Peter Leedman, K.P. Lam, C.C. Goodnow, C.G. Vinuesa

    Research output: Contribution to journalArticlepeer-review

    366 Citations (Scopus)


    Immune responses are normally targeted against microbial pathogens and not self-antigens by mechanisms that are only partly understood. Here we define a newly discovered pathway that prevents autoimmunity by limiting the levels on T lymphocytes of a co-stimulatory receptor, the inducible T-cell co-stimulator (ICOS). In sanroque mice homozygous for an M199R mutation in the ROQ domain of Roquin (also known as Rc3h1)(1), increased Icos expression on T cells causes the accumulation of lymphocytes that is associated with a lupus-like autoimmune syndrome. Roquin normally limits Icos expression by promoting the degradation of Icos messenger RNA. A conserved segment in the unusually long ICOS 39 untranslated mRNA is essential for regulation by Roquin. This segment comprises a 47-base-pair minimal region complementary to T-cell-expressed microRNAs including miR-101, the repressive activity of which is disrupted by base-pair inversions predicted to abrogate miR-101 binding. These findings illuminate a critical post-transcriptional pathway within T cells that regulates lymphocyte accumulation and autoimmunity, and highlights the therapeutic potential of partially antagonising the ICOS pathway.
    Original languageEnglish
    Pages (from-to)299-303
    Issue number8
    Publication statusPublished - 2007


    Dive into the research topics of 'Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA'. Together they form a unique fingerprint.

    Cite this